Cardio Metabolic Risk Factors for Atrial Fibrillation in Type 2 Diabetes Mellitus: Focus on Hypertension, Metabolic Syndrome and Obesity
Highlights
- Patients with type 2 diabetes mellitus are at increased risk of developing atrial fibrillation.
- Hypertension, metabolic syndrome and obesity are important cardio metabolic risk factors for atrial fibrillation in patients with type 2 diabetes mellitus.
Abstract
:Highlights
- Patients with type 2 diabetes mellitus are at increased risk of developing atrial fibrillation.
- Hypertension, metabolic syndrome and obesity are important cardio metabolic risk factors for atrial fibrillation in patients with type 2 diabetes mellitus.
Abstract
Introduction
Materials and Methods
Study design
Setting
Participants
Data sources and variables
Bias
Statistical methods
Ethical standards
Results
Discussions
Conclusions
Author contribution
Acknowledgements
Conflict of interest disclosure
Compliance with ethical standards
References
- Morin, D.P.; Bernard, M.L.; Madias, C.; Rogers, P.A.; Thihalolipavan, S.; Estes, N.A. The state of the art: atrial fibrillation epidemiology, prevention, and treatment. Mayo Clin Proc. 2016, 91, 1778–1810. [Google Scholar] [CrossRef] [PubMed]
- Colilla, S.; Crow, A.; Petkun, W.; Singer, D.E.; Simon, T.; Liu, X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013, 112, 1142–1147. [Google Scholar] [CrossRef] [PubMed]
- Gargavu, S.R.; Clenciu, D.; Rosu, M.M.; Tenea-Cojan, T.S.; Costache, A.; Vladu, I.M.; Mota, M. The assessment of life style and the visceral adiposity index as cardiometabolic risk factors. Arch Balk Med Union. 2018, 53, 189–195. [Google Scholar] [CrossRef]
- Pusta, C.T.; Mihalache, G.; Buhas, C.; Pop, O. A rare case of cardiac fibroma in a death truck driver. Rom J Leg Med. 2015, 23, 247–250. [Google Scholar] [CrossRef]
- Gargavu, S.R.; Clenciu, D.; Rosu, M.M.; Tenea Cojan, T.S.; Costache, A.; Vladu, I.M.; Mota, M. Visceral Adiposity Index (VAI) – a potential marker of cardiometabolic risk. Arch Balk Med Union. 2018, 53, 246–251. [Google Scholar] [CrossRef]
- Pallisgaard, J.L.; Schjerning, A.M.; Lindhardt, T.B.; Procida, K.; Hansen, M.L.; Torp-Pedersen, C.; Gislason, G.H. Risk of atrial fibrillation in diabetes mellitus: A nationwide cohort study. Eur J Prev Cardiol. 2016, 23, 621–627. [Google Scholar] [CrossRef] [PubMed]
- Cozma, A.; Sitar-Taut, A.; Urian, L.; Fodor, A.; Suharoschi, R.; Muresan, C.; Negrean, V.; Sampelean, D.; Zdrenghea, D.; Pop, D.; Leucuta, D.; Orasan, O.H. Unhealthy lifestyle and the risk of metabolic syndrome- the Romanian experience. J Mind Med Sci. 2018, 5, 218–229. [Google Scholar] [CrossRef]
- Andrade, J.; Khairy, P.; Dobrev, D.; Nattel, S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014, 114, 1453–1468. [Google Scholar] [CrossRef] [PubMed]
- Mashat, A.A.; Subki, A.H.; Bakhaider, M.A.; Baabdullah, W.M.; Walid, J.B.; Alobudi, A.H.; Fakeeh, M.M.; Algethmi, A.J.; Alhejily, W.A. Atrial fibrillation: risk factors and comorbidities in a tertiary center in Jeddah, Saudi Arabia. Int J Gen Med. 2019, 12, 71–77. [Google Scholar] [CrossRef] [PubMed]
- Rowley, W.R.; Bezold, C.; Arikan, Y.; Byrne, E.; Krohe, S. Diabetes 2030: Insights from yesterday, today, and future trends. Popul Health Manag. 2017, 20, 6–12. [Google Scholar] [CrossRef] [PubMed]
- Zethelius, B.; Gudbjörnsdottir, S.; Eliasson, B.; Eeg-Olofsson, K.; Svensson, A.M.; Cederholm, J. Risk factors for atrial fibrillation in type 2 diabetes: report from the Swedish National Diabetes Register (NDR). Diabetologia. 2015, 58, 2259–2268. [Google Scholar] [CrossRef] [PubMed]
- Boiko, V.V.; Biletskyi, S.V.; Petrynych, O.A.; Kazantseva, T.V.; Sheremet, M.I. Influence of the PPARgamma2 gene polymorphism on some metabolic indices in patients with essential aterial hypertension accompanied by ischemic heart disease and type 2 diabetes mellitus. Arch Balk Med Union. 2018, 53, 29–34. [Google Scholar]
- Bell, D.S.H.; Goncalves, E. Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab. 2019, 21, 210–217. [Google Scholar] [CrossRef] [PubMed]
- Liang, X.; Zhang, Q.; Wang, X.; Yuan, M.; Zhang, Y.; Xu, Z.; Li, G.; Liu, T. Reactive oxygen species mediated oxidative stress links diabetes and atrial fibrillation. Mol Med Rep. 2018, 17, 4933–4940. [Google Scholar] [CrossRef] [PubMed]
- Gaman, A.M.; Buga, A.M.; Gaman, M.A.; Popa-Wagner, A. The role of oxidative stress and the effects of antioxidants on the incidence of infectious complications of chronic lymphocytic leukemia. Oxid Med Cell Longev. 2014, 2014, 158135. [Google Scholar] [CrossRef] [PubMed]
- Rusu, A.; Bala, C.G.; Craciun, A.E.; et al. HbA1c levels are associated with severity of hypoxemia and not with apnea hypopnea index in patients with type 2 diabetes: results from a cross-sectional study. Journal of Diabetes. 2017, 9, 555–561. [Google Scholar] [CrossRef] [PubMed]
- Motofei, I.G.; Rowland, D.L.; Popa, F.; Bratucu, E.; Straja, D.; Manea, M.; Georgescu, S.R.; Paunica, S.; Bratucu, M.; Balalau, C.; Constantin, V.D. A Pilot Study on Tamoxifen Sexual Side Effects and Hand Preference in Male Breast Cancer. Arch Sex Behav. 2015, 44, 1589–1594. [Google Scholar] [CrossRef] [PubMed]
- Moss, A.S.; Dimitropoulos, G.; Connolly, D.L.; Lip, G.Y.H. Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus. Expert Opin Pharmacother. 2017, 18, 1101–1114. [Google Scholar] [CrossRef] [PubMed]
- Tantu, M.M.; Man, G.M.; Paunescu, A.; et al. Correlations between the use of medical substances and the incidence infections produced by Clostridium difficile species. Rev Chim (Bucharest). 2018, 69, 3001–3005. [Google Scholar] [CrossRef]
© 2019 by the author. 2019 Mihnea A. Găman, Elena C. Dobrică, Emilia G. Pascu, Matei A. Cozma, Mirela E. Epîngeac, Amelia M. Găman, Anca P. Stoian, Ovidiu G. Bratu, Camelia C. Diaconu
Share and Cite
Găman, M.A.; Dobrică, E.C.; Pascu, E.G.; Cozma, M.A.; Epîngeac, M.E.; Găman, A.M.; Stoian, A.P.; Bratu, O.G.; Diaconu, C.C. Cardio Metabolic Risk Factors for Atrial Fibrillation in Type 2 Diabetes Mellitus: Focus on Hypertension, Metabolic Syndrome and Obesity. J. Mind Med. Sci. 2019, 6, 157-161. https://doi.org/10.22543/7674.61.P157161
Găman MA, Dobrică EC, Pascu EG, Cozma MA, Epîngeac ME, Găman AM, Stoian AP, Bratu OG, Diaconu CC. Cardio Metabolic Risk Factors for Atrial Fibrillation in Type 2 Diabetes Mellitus: Focus on Hypertension, Metabolic Syndrome and Obesity. Journal of Mind and Medical Sciences. 2019; 6(1):157-161. https://doi.org/10.22543/7674.61.P157161
Chicago/Turabian StyleGăman, Mihnea A., Elena C. Dobrică, Emilia G. Pascu, Matei A. Cozma, Mirela E. Epîngeac, Amelia M. Găman, Anca P. Stoian, Ovidiu G. Bratu, and Camelia C. Diaconu. 2019. "Cardio Metabolic Risk Factors for Atrial Fibrillation in Type 2 Diabetes Mellitus: Focus on Hypertension, Metabolic Syndrome and Obesity" Journal of Mind and Medical Sciences 6, no. 1: 157-161. https://doi.org/10.22543/7674.61.P157161
APA StyleGăman, M. A., Dobrică, E. C., Pascu, E. G., Cozma, M. A., Epîngeac, M. E., Găman, A. M., Stoian, A. P., Bratu, O. G., & Diaconu, C. C. (2019). Cardio Metabolic Risk Factors for Atrial Fibrillation in Type 2 Diabetes Mellitus: Focus on Hypertension, Metabolic Syndrome and Obesity. Journal of Mind and Medical Sciences, 6(1), 157-161. https://doi.org/10.22543/7674.61.P157161